Biotech · Private company · San Diego, CA, US
Mark Therapeutics, Inc.
Track this companyFree. Adds Mark Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Gene Therapy for Idiopathic Parkinson's Disease: In Vivo ValidationFiscal year 2026 · $862.5KNIH RePORTER 2R44NS134446-03 · fetched Nov 12, 2026
- Gene Therapy for Idiopathic Parkinson's DiseaseFiscal year 2025 · $192.2KNIH RePORTER 5R43NS134446-02 · fetched Nov 12, 2026
- Gene Therapy for Idiopathic Parkinson's DiseaseFiscal year 2024 · $494KNIH RePORTER 1R43NS134446-01A1 · fetched Nov 12, 2026